en
At the Formulation & Delivery US 2024 conference, Crystal Formulation Services (Crystal Pharmatech's CDMO BU) will present a technical case study centered on the formulation and development process of First-In-Human (FIH) enteric-coated tablets at three dose strengths for an amorphous prodrug highly susceptible to hydrolysis under both acidic and basic conditions. We will delve into the scientific approaches employed to mitigate degradation pathways, ensure product stability through carefully selected excipients and optimized manufacturing techniques, and how material science-based approaches can lead to successful FIH product development within tight timelines.
Attendee:
Jessica (Xiaoxia) Chen, Ph.D. (Speaker)
Decheng Ma, Ph.D.
Date: October 16-17, 2024
Location: DoubleTree by Hilton Hotel San Diego - Mission Valley
Booth: 12
First in Human (FIH) Tablet Development for an Amorphous Unstable Prodrug with Enteric Coating Using an API Sparing Approach
Ready for an evening of unscripted connection?
Please complete the form to register for our San Diego Biotech and Pharma R&D social. Note: Registration is subject to review. You will receive a formal confirmation email once your attendance is approved.
By providing your e-mail address, you agree to receive an e-mail response from Crystal Pharmatech to your registration. The information you submit will be governed by our Privacy Policy.
_.webp "A Significant Step Toward Greater Clarity in Polymorph Control for Innovative Drugs")
Subscribe to be the first to get the updates!
